Data updated: May 26, 2026
DEUTETRABENAZINE
CNS
Approved 2024-12-26
1
Indication
--
Phase 3 Trials
1
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2024-12-26
- Routes
- ORAL
- Dosage Forms
- TABLET
DEUTETRABENAZINE Approval History
2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 2024 to 2026
May 2026 SUPPL
Label · Labeling
What DEUTETRABENAZINE Treats
1 FDA approvalsOriginally approved for its first indication in 2024 .
- Other (1)
Other
(1 approval)- • Approved indication (Dec 2024)Letter
📋
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT04713982 | 200069 | Ph 2, Ph 3 | active not recruiting | Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DEUTETRABENAZINE FDA Label Details
Looking for the branded version?
AUSTEDO
Full clinical data, patents, trials, and competitive landscape for deutetrabenazine.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.